Ziopharm Oncology Inc (ZIOP) 3.27 $ZIOP
ZIOPHARM Reports First-Quarter 2014 Financial Results and Reviews Recent Activities
GlobeNewswire - Thu May 08, 3:48PM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the first quarter ended March 31, 2014, and provided an update on the company's product development activities.
Amicus Therapeutics (FOLD) Jumps: Stock Up 20.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 8:39AM CDT
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as its shares rose nearly 21% on the day.
GTX Inc. (GTXI) Jumps: Stock Up 14.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 7:51AM CDT
GTX Inc. (GTXI) was a big mover last session, as its shares rose over 14% on the day.
Investors are betting against ZIOPHARM (ZIOP), Should You? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 6:24AM CDT
Investors are betting against ZIOPHARM (ZIOP), Should You?
Johnson & Johnson Boosts Dividend 6.1% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 5:00PM CDT
Johnson & Johnson (JNJ) raised its quarterly dividend to 70 cents per share , representing an increase of 6.1% over the previous payout.
Top Gainers on the Move -- Research on Arrowhead Research, Endocyte, Ambac Financial, and ZIOPHARM Oncology
PR Newswire - Wed Apr 23, 11:40AM CDT
The trading session on Tuesday, April 22, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,514.37, up 0.40% and the NASDAQ Composite closed at 4,161.46, up 0.97%. The S&P 500 finished the session 0.41% higher at 1,879.55. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including Arrowhead Research Corp. (NASDAQ: ARWR), Endocyte Inc. (NASDAQ: ECYT), Ambac Financial Group Inc. (NASDAQ: AMBC) and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP). Free technical research on ARWR, ECYT, AMBC and ZIOP can be downloaded upon signing up at:
Global Peripheral T-Cell Lymphomas (PTCL) Therapeutics Pipeline Review 2014 - Analysis of 12 Companies & 22 Drug Profiles
M2 - Wed Apr 23, 8:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6sbss/peripheral_tcell) has announced the addition of the "Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peripheral T-Cell Lymphomas (PTCL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peripheral T-Cell Lymphomas (PTCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peripheral T-Cell Lymphomas (PTCL) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - ZIOPHARM Oncology, Inc. - Millennium Pharmaceuticals, Inc. - Eisai Co., Ltd. - Celgene Corporation - Incyte Corporation - Topotarget A/S - Mundipharma International Limited - Spectrum Pharmaceuticals, Inc. - Chipscreen Biosciences Ltd - CerRx, Inc. - Rhizen Pharmaceuticals SA Drug Profiles - belinostat - mogamulizumab - pralatrexate - pralatrexate - romidepsin - alisertib - pralatrexate - romidepsin - HBI-8000 - belinostat - mogamulizumab - ruxolitinib phosphate - darinaparsin - romidepsin - fenretinide - forodesine hydrochloride - pralatrexate - darinaparsin - denileukin diftitox - alefacept - TGR-1202 - darinaparsin For more information visit http://www.researchandmarkets.com/research/m6...eral_tcell
Revance Therapeutics (RVNC) Soars: Stock Up 25.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 8:39AM CDT
Revance Therapeutics, Inc. was a big mover last session, as its shares rose nearly 26% on the day.
Cytokinetics, Incorporated (CYTK) Jumps: Stock Up 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 8:39AM CDT
Cytokinetics, Incorporated was a big mover last session, as its shares rose nearly 14% on the day.
Sarepta Therapeutics (SRPT) Soars: Stock Up 39.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 7:51AM CDT
Sarepta Therapeutics, Inc. was a big mover last session, as its shares rose over 39% on the day.
Emergent BioSolutions Gains on Trial News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 4:10PM CDT
Emergent BioSolutions is looking to expand BioThrax's label.
Transition Therapeutics (TTHI) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:51AM CDT
Transition Therapeutics Inc. was a big mover last session, as its shares rose nearly 12% on the day.
Amicus Therapeutics (FOLD) Crumbles: Stock Falls by 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:33AM CDT
Amicus has not seen any positive earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Research and Markets: Global Testicular Cancer Drugs Market 2014-2018 With Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating
Business Wire - Wed Apr 16, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cc3342/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering.
Global Testicular Cancer Drugs Market 2014-2018 with Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating
M2 - Wed Apr 16, 3:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7567b6/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering. One of the key drivers is the increasing prevalence of testicular cancer due to a variety of factors such as congenital abnormalities, family history, abnormal testicular development, and HIV infection. This has increased the demand for testicular cancer drugs as these drugs have greatly improved survival rate for patients with both seminomas and non-seminomas type of testicular cancer. The current trend witnessed by the Global Testicular Cancer Drugs market is combination therapy being used for treating testicular cancer. Several oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapy helps in completely removing the tumor or destroying the cancerous cells in the patient's body. The combination therapy is decided depending on the size of the tumor and the risk of recurrence. Moreover, for treatment of testicular cancer, a combination of two or more drugs is usually given. Some of the combinations are BEP, EP (etoposide and cisplatin), and VIP (vinblastine plus ifosfamide and cisplatin). Further, the report states that one of the main challenges in the market is the presence of alternative testicular cancer treatments that do not use drugs, thereby limiting the consumption of drugs. Key vendors dominating this space include: - Bristol-Myers Squibb Co - Hospira Inc. - Teva Pharmaceutical Industries Ltd. - ZIOPHARM Oncology Inc. Other vendors mentioned in the report are: - Baxter International Inc. - Fresenius Kabi Pharmaceuticals Holding Inc. - Mylan Pharmaceutical Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Testicular Cancer by Type - Testicular Cancer Disease by Stages - Treatment Options - Clinical Trial Snapshot - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/75...testicular
Positive Data on Biogen/Sobi's Eloctate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 10:40AM CDT
Biogen/Sobi reported positive top-line data on their hemophilia A candidate, Eloctate from a phase III pediatric study (Kids A-LONG).
Rite Aid (RAD) Jumps: Stock Up 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:39AM CDT
Rite Aid Corporation was a big mover last session, as its shares rose over 8% on the day.
Celladon (CLDN) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:51AM CDT
Celladon Corporation was a big mover last session, as its shares rose nearly 12% on the day.
Gentiva Health Slumps: GTIV Falls 6.0% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:33AM CDT
Shares of Gentiva Health fell over 6% on the day. This breaks the recent trend of the company, as the stock is now trading below the volatile price range of $8.5 to $9.5 in the past one-month time frame. This home health services provider company has seen a flat track record when it comes to current year estimate revisions.
Halozyme Study Under Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:40PM CDT
Halozyme announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on patient enrollment and dosing of PEGPH20 in an ongoing phase II study.
ZIOPHARM Reports First-Quarter 2014 Financial Results and Reviews Recent Activities
GlobeNewswire - Thu May 08, 3:48PM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the first quarter ended March 31, 2014, and provided an update on the company's product development activities.
Amicus Therapeutics (FOLD) Jumps: Stock Up 20.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 8:39AM CDT
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as its shares rose nearly 21% on the day.
GTX Inc. (GTXI) Jumps: Stock Up 14.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 7:51AM CDT
GTX Inc. (GTXI) was a big mover last session, as its shares rose over 14% on the day.
Investors are betting against ZIOPHARM (ZIOP), Should You? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 6:24AM CDT
Investors are betting against ZIOPHARM (ZIOP), Should You?
Johnson & Johnson Boosts Dividend 6.1% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 5:00PM CDT
Johnson & Johnson (JNJ) raised its quarterly dividend to 70 cents per share , representing an increase of 6.1% over the previous payout.
Top Gainers on the Move -- Research on Arrowhead Research, Endocyte, Ambac Financial, and ZIOPHARM Oncology
PR Newswire - Wed Apr 23, 11:40AM CDT
The trading session on Tuesday, April 22, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,514.37, up 0.40% and the NASDAQ Composite closed at 4,161.46, up 0.97%. The S&P 500 finished the session 0.41% higher at 1,879.55. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including Arrowhead Research Corp. (NASDAQ: ARWR), Endocyte Inc. (NASDAQ: ECYT), Ambac Financial Group Inc. (NASDAQ: AMBC) and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP). Free technical research on ARWR, ECYT, AMBC and ZIOP can be downloaded upon signing up at:
Global Peripheral T-Cell Lymphomas (PTCL) Therapeutics Pipeline Review 2014 - Analysis of 12 Companies & 22 Drug Profiles
M2 - Wed Apr 23, 8:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6sbss/peripheral_tcell) has announced the addition of the "Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peripheral T-Cell Lymphomas (PTCL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peripheral T-Cell Lymphomas (PTCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peripheral T-Cell Lymphomas (PTCL) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - ZIOPHARM Oncology, Inc. - Millennium Pharmaceuticals, Inc. - Eisai Co., Ltd. - Celgene Corporation - Incyte Corporation - Topotarget A/S - Mundipharma International Limited - Spectrum Pharmaceuticals, Inc. - Chipscreen Biosciences Ltd - CerRx, Inc. - Rhizen Pharmaceuticals SA Drug Profiles - belinostat - mogamulizumab - pralatrexate - pralatrexate - romidepsin - alisertib - pralatrexate - romidepsin - HBI-8000 - belinostat - mogamulizumab - ruxolitinib phosphate - darinaparsin - romidepsin - fenretinide - forodesine hydrochloride - pralatrexate - darinaparsin - denileukin diftitox - alefacept - TGR-1202 - darinaparsin For more information visit http://www.researchandmarkets.com/research/m6...eral_tcell
Revance Therapeutics (RVNC) Soars: Stock Up 25.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 8:39AM CDT
Revance Therapeutics, Inc. was a big mover last session, as its shares rose nearly 26% on the day.
Cytokinetics, Incorporated (CYTK) Jumps: Stock Up 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 8:39AM CDT
Cytokinetics, Incorporated was a big mover last session, as its shares rose nearly 14% on the day.
Sarepta Therapeutics (SRPT) Soars: Stock Up 39.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 7:51AM CDT
Sarepta Therapeutics, Inc. was a big mover last session, as its shares rose over 39% on the day.
Emergent BioSolutions Gains on Trial News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 4:10PM CDT
Emergent BioSolutions is looking to expand BioThrax's label.
Transition Therapeutics (TTHI) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:51AM CDT
Transition Therapeutics Inc. was a big mover last session, as its shares rose nearly 12% on the day.
Amicus Therapeutics (FOLD) Crumbles: Stock Falls by 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:33AM CDT
Amicus has not seen any positive earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Research and Markets: Global Testicular Cancer Drugs Market 2014-2018 With Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating
Business Wire - Wed Apr 16, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cc3342/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering.
Global Testicular Cancer Drugs Market 2014-2018 with Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating
M2 - Wed Apr 16, 3:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7567b6/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering. One of the key drivers is the increasing prevalence of testicular cancer due to a variety of factors such as congenital abnormalities, family history, abnormal testicular development, and HIV infection. This has increased the demand for testicular cancer drugs as these drugs have greatly improved survival rate for patients with both seminomas and non-seminomas type of testicular cancer. The current trend witnessed by the Global Testicular Cancer Drugs market is combination therapy being used for treating testicular cancer. Several oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapy helps in completely removing the tumor or destroying the cancerous cells in the patient's body. The combination therapy is decided depending on the size of the tumor and the risk of recurrence. Moreover, for treatment of testicular cancer, a combination of two or more drugs is usually given. Some of the combinations are BEP, EP (etoposide and cisplatin), and VIP (vinblastine plus ifosfamide and cisplatin). Further, the report states that one of the main challenges in the market is the presence of alternative testicular cancer treatments that do not use drugs, thereby limiting the consumption of drugs. Key vendors dominating this space include: - Bristol-Myers Squibb Co - Hospira Inc. - Teva Pharmaceutical Industries Ltd. - ZIOPHARM Oncology Inc. Other vendors mentioned in the report are: - Baxter International Inc. - Fresenius Kabi Pharmaceuticals Holding Inc. - Mylan Pharmaceutical Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Testicular Cancer by Type - Testicular Cancer Disease by Stages - Treatment Options - Clinical Trial Snapshot - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/75...testicular
Positive Data on Biogen/Sobi's Eloctate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 10:40AM CDT
Biogen/Sobi reported positive top-line data on their hemophilia A candidate, Eloctate from a phase III pediatric study (Kids A-LONG).
Rite Aid (RAD) Jumps: Stock Up 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:39AM CDT
Rite Aid Corporation was a big mover last session, as its shares rose over 8% on the day.
Celladon (CLDN) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:51AM CDT
Celladon Corporation was a big mover last session, as its shares rose nearly 12% on the day.
Gentiva Health Slumps: GTIV Falls 6.0% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:33AM CDT
Shares of Gentiva Health fell over 6% on the day. This breaks the recent trend of the company, as the stock is now trading below the volatile price range of $8.5 to $9.5 in the past one-month time frame. This home health services provider company has seen a flat track record when it comes to current year estimate revisions.
Halozyme Study Under Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:40PM CDT
Halozyme announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on patient enrollment and dosing of PEGPH20 in an ongoing phase II study.
